Bolt Biotherapeutics, Inc.

NasdaqCM:BOLT 株式レポート

時価総額：US$7.6m

Bolt Biotherapeutics 過去の業績

過去 基準チェック /06

Bolt Biotherapeuticsは20.6%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで34.1%毎年増加している。売上は成長しており、年平均18.4%の割合である。

主要情報

20.61%

収益成長率

30.45%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率18.42%
株主資本利益率-227.37%
ネット・マージン-611.47%
前回の決算情報30 Jun 2026

最近の業績更新

Recent updates

分析記事 • Nov 30

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • May 21

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Bolt Biotherapeutics, Inc. ( NASDAQ:BOLT ) shareholders that were waiting for something to happen have been dealt a...
分析記事 • Mar 15

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Dec 01

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 26

Bolt Biotherapeutics: A Promised Follow Up

Summary Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third of the cash on its balance sheet. We update the investment thesis around Bolt Biotherapeutics in the paragraphs below. "Pride is always a better lever against the nobility than reason." - Patrick Rothfuss, The Wise Man's Fear In our first article on biotech name Bolt Biotherapeutics, Inc. (BOLT) back in September of last year, we concluded by saying the company had some "potentially intriguing technology" but it was not investment worthy at the time. We also promised we would check back in on this name to see how it was progressing. Today, we follow up on Bolt Biotherapeutics via the analysis below. Seeking Alpha Company Overview: Bolt Biotherapeutics is headquartered in California. The company is developing drug candidates using its Boltbody immune-stimulating antibody conjugate (ISAC) platform. This technology is being applied to create a new category of immunotherapies that generate a robust anti-tumor immune response by combining the precision of antibody targeting with the strength of the innate and adaptive immune systems. By activating and recruiting myeloid cells, Boltbody ISACs re-program the tumor microenvironment to invoke a new anti-tumor immune response. Company Website Myeloid cells are a group of immune cells that belong to the innate immune system. They consist of cell types known as monocytes, macrophages, dendritic cells, and granulocytes. These cells serve many essential roles in the body's immune system. When these cells are functioning properly, they can stimulate anti-tumor effects in the body. Including the activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory. Immunosuppressive factors produced in the tumor microenvironment can impair the normal function of these cells. The stock currently trades around two bucks a share and sports an approximate market capitalization of $75 million. Recent Developments: The biggest news around the company since we last peaked in on it occurred early in December of last year. Bolt Biotherapeutics presented interim clinical data from its Phase 1/2 study of BDC-1001, its lead candidate, at the European Society for Medical Oncology Immuno-Oncology Congress. Early data showed 13 of the 40 tumor evaluable subjects with one durable partial response maintained through 52 weeks and multiple subjects achieving stable disease for >12 weeks. BDC - 1001 is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. This data was good enough to support initiation of the combination therapy study with nivolumab, also known by its brand name Opdivo from Bristol-Myers Squibb (BMY). That said, the data did not meet investors' expectations as the market cut the stock in roughly half after interim results from the study became known. Weekly dosing with a study around a combination therapy with Opdivo has begun and should be noted. Company Website The company has one other compound in development currently. It is called BDC-3042. This candidate is a myeloid modulating agonist antibody that reawakens myeloid cells to attack tumor cells. Specifically, BDC-3042 will stimulate a novel target called Dectin-2. This is found in tumor-associated macrophages across a broad range of solid tumors. Stimulating Dectin-2 leads to tumor macrophage reprogramming and anti-cancer activity in the company's preclinical studies. BDC-3042 will target solid tumors with a high unmet lead. However, BDC-3042 is still in the pre-clinical phase and is currently in IND-enabling studies. Analyst Commentary & Balance Sheet: Analysts are mixed on Bolt's prospects at the moment. Morgan Stanley has a Hold rating on the stock. On August 11th, SVP Securities downgraded Bolt from Outperform to Market Perform and slashed its price target in half to $4 a share. SVB's analyst noted he sees "A long road to recovery" following the company's announced discontinuation of second Boltbody candidate BDC-2034, which was previously on track to enter the clinic in 2023. The discontinuation was prompted by non-human primate fatalities observed at mid- to high-dose levels in toxicology studies. That same day, both Stifel Nicolaus ($7 price target) and JonesTrading ($8 price target) maintained Buy ratings on Bolt Biotherapeutics. The company ended the second quarter with just over $220 million in cash and marketable securities on its balance sheet. Bolt burned through around $23 million during the quarter to fund all operations. The company has no long-term debt. Management has put in place measures to conserve cash as was summarized in its second quarter earnings press release.
Seeking Alpha • Aug 10

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Bolt Biotherapeutics press release (NASDAQ:BOLT): Q2 GAAP EPS of -$0.61 beats by $0.08. Revenue of $1.39M beats by $0.89M.
分析記事 • Jul 27

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Apr 12

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Dec 03

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 18

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

Bolt has built out a next-generation immunotherapy platform to design biologics for cancers that are not accessible for the current standard-of-care. The company's lead asset, BDC-1001, is expected to complete phase 1 clinical trials later this year creating a window for an opportunistic investment. As the pipeline matures, Bolt will be able to build out their partnerships and transition their business toward a fully-integrated diversified model.
分析記事 • Aug 18

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

収支内訳

Bolt Biotherapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:BOLT 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 265-29120
31 Mar 266-30130
31 Dec 258-33140
30 Sep 255-43150
30 Jun 254-51150
31 Mar 254-6316-1
31 Dec 248-63180
30 Sep 2410-65200
30 Jun 2411-66220
31 Mar 2411-63231
31 Dec 238-69230
30 Sep 237-71230
30 Jun 237-77220
31 Mar 237-81220
31 Dec 226-88230
30 Sep 225-95220
30 Jun 223-97220
31 Mar 222-98200
31 Dec 211-99180
30 Sep 211-102150
30 Jun 210-89130
31 Mar 210-77110
31 Dec 200-6190
30 Sep 200-3990
30 Jun 200-3680
31 Mar 200-3260
31 Dec 190-3050

質の高い収益: BOLTは現在利益が出ていません。

利益率の向上: BOLTは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: BOLTは利益を出していないが、過去 5 年間で年間20.6%の割合で損失を削減してきた。

成長の加速: BOLTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BOLTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 64.6% ) と比較することは困難です。

株主資本利益率

高いROE: BOLTは現在利益が出ていないため、自己資本利益率 ( -227.37% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/14 18:56
終値2026/09/14 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bolt Biotherapeutics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6

アナリスト機関
Robert BurnsH.C. Wainwright & Co.
Boris PeakerJonesTrading Institutional Services, LLC
Chad MesserLake Street Capital Markets, LLC